Riesgo de acidosis láctica fatal y no fatal con el uso de metformina para la diabetes mellitus tipo 2
Characteristics of included studies Participants
COUNTRY: Germany SETTING: outpatient Treatment N: 40 Control N: 20 AGE: unclear SEX: 55% males INCLUSION: Type 2 DM EXCLUSIONS: none listed
Interventions
TREATMENT: Metformin, dosage unclear, or metformin + insulin COMPARISON: Sulfonylurea
Outcomes
Lipids, liver function studies, and glucose.
Notes Allocation concealment
D
Study
Nagi 1993
Methods
TRIAL DESIGN: Double-blind crossover randomised controlled trial DURATION: 3 months
Participants
COUNTRY: United States. SETTING: outpatient. Treatment N: 27. Control N: 27. Age: 56.8 +/-8.9. Sex: not listed. Inclusion: Type 2 DM. Exclusions: cardiovascular disease, thromboembolic disease, renal or hepatic disease, retinopathy.
Interventions
TREATMENT: Metformin, dosage adjusted clinically. COMPARISON: placebo
Outcomes
Fasting glucose, lipids, BMI, insulin, c-peptide, blood pressure, plasminogen activator inhibitor, and other factors
Notes Allocation concealment
B
Study
Natali 2004
Methods
TRIAL DESIGN: Double-blind randomised controlled trial DURATION: 4 months
Participants
COUNTRY: Italy SETTING: outpatient: Treatment N: 28 Control N: 46 Age: 58 +/- 9 Sex: 70% men Inclusion: type 2 DM Exclusions: renal or hepatic dysfrunction, congestive heart failure
Interventions
TREATMENT: Metformin 500 mg TID COMPARISON: placebo
Outcomes
Insulin sensitivity by euglycemic clamp, fat-free mass, response to acetycholine
Notes Allocation concealment
D
Página 75
Copyright © John Wiley & Sons Ltd. Usado con permiso de John Wiley & Sons, Ltd.